HCM - HUTCHMED DRC
HUTCHMED DRC Logo

HCM - HUTCHMED DRC

https://www.hutch-med.com
Recent News
Powered by Alpha Vantage
AI Tools
Key Metrics
Trend: Downtrend
Source: Snapshot

HUTCHMED (China) Limited discovers, develops and markets targeted immunotherapies and therapies for cancer and immune diseases globally. The company is headquartered in Central, Hong Kong.

52W High
$21.50
52W Low
$11.51
MA Status:
50D: Below 200D: Below
Beta (~1 neutral, <0.9 lower risk)
0.47
Valuation
Rich
As of 2024-12-31 (Overview)
Trailing P/E (<15 better)
6.03
Forward P/E (<15 better)
322.58
EV/EBITDA (<8 favorable)
37.55
EV/Revenue (<3 favorable)
2.37
P/S (TTM) (<3 favorable)
4.56
P/B (<3 favorable)
2.23
Ownership
Retail‑heavy
Source: Overview
Insiders (1–5% typical)
0.13%
Institutions (25–75% balanced)
3.63%
Shares Outstanding
171,860,000
Float
509,007,000
Dividend Yield (2–6% sweet spot)
N/A
Ex‑Dividend Date
N/A
Income & Growth
Profitability: Weak
As of 2024-12-31 (Overview)
Revenue (TTM)
602,197,000
Gross Profit (TTM)
53,762,000
EPS (TTM)
2.65
Profit Margin (>10% good)
0.78%
Operating Margin (TTM) (higher better)
-0.01%
ROE (TTM) (>15% strong)
0.47%
EPS YoY (Quarterly) (>10% good)
16.33
Revenue YoY (Quarterly) (>8% good)
-0.09
Momentum
Value
N/A
Previous
N/A
Trend
—
Signal Cross
No cross
As of
—